Sagimet Biosciences Inc. Series A Common Stock (SGMT) Valuation & Financial Model
Interactive Discounted Cash Flow (DCF) model for Sagimet Biosciences Inc. Series A Common Stock (US:SGMT), currently being evaluated. In 2023, Sagimet Biosciences Inc. Series A Common Stock generated $2.00 Million in revenue and -$23.77 Million in free cash flow. Explore projected intrinsic value assumptions based on institutional-grade macro metrics.
Valuation Methodology & Recent Performance
The financial model for Sagimet Biosciences Inc. Series A Common Stock is calculated using an institutional discounted cash flow (DCF) engine utilizing recent operational metrics:
- Current Price: N/A
- Recent Revenue (2023): $2.00 Million
- Free Cash Flow (2023): -$23.77 Million
- Discount Rate (WACC): Derived using the Risk-Free Rate (e.g., 10Y Gov Bond) plus an Equity Risk Premium based on market volatility and stock price variance.
- Terminal Value: Projected using a perpetual growth model bounded by long-term macroeconomic estimates.